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Glassy cell carcinoma (GCC) of the uterine cervix is relatively very
rare, comprising b1% of all cervical cancers. GCC is a poorly differen-
tiated adenosquamous carcinoma with distinctive microscopic fea-
tures, including ground glass-type cytoplasm, prominent nucleoli,
an absence of intercellular brides, and eosinophilic inﬂammatory
cell inﬁltration of the stroma. The clinical course of GCC is aggressive,
and radiation and surgery are rarely curative for patientswith advanced
disease. Furthermore, very little is known regarding the use of chemo-
therapy for this cancer. In the neodjuvant setting, a clinical response
to chemotherapy was described in 4 reports from Japanese centers, 3
of which were conducted using intraarterial chemotherapy and an in-
terventional radiological technique (Mikami et al., 2000; Nagai et al.,
2008). There was also a case report of a paclitaxel and carboplatin
(TC) intravenous regimen used to treat 1 patient (Takekuma et al.,
2006), and 2 other case reports that described a response of recurrent
GCC to TC therapy (Hirashima et al., 2001; Matsuura et al., 2001).
Here we report a case of primary metastatic GCC of the uterine cervix,
which responded to intravenous chemotherapy with docetaxel and
carboplatin (DC).⁎ Corresponding author. Fax: +81 798 46 4163.
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A 61-year-old woman, G5P3, was referred to us because of abnor-
mal genital bleeding. Vaginal examination revealed an exophytic
tumor 5 cm in diameter originating in the cervical canal, and a nor-
mal cervix. The pedunculated tumor was excised by the same proce-
dure as that used for the vaginal removal of prolapsed pedunculated
submucous myoma. Histological examination of the specimen revealed
large polygonal cells containing a distinct nucleolus and cytoplasmwith
a ground glass appearance. In addition, the stroma was diffusely inﬁl-
trated by lymphoplasmacytic cells. On the basis of these ﬁndings, the
tumor was diagnosed as a GCC (Fig. 1A, B), and a careful examination
was conducted because of the possibility of some residual cancer. Her
32.4 ng/ml, respectively, and a Pap smear or cervical biopsy and curet-
tage showed no malignancy. Magnetic resonance imaging (MRI) and
18-ﬂudeooxyglucose positron emission tomography/computed tomog-
raphy (18-FDG PET/CT) scans showed multiple retroperitoneal and
supraclavicular lymph node metastases, although no residual tumor
was found in the uterus (Fig. 2A–C). Therefore, systemic chemotherapy
was administered, but no radical hysterectomy was performed.
The patient was treated with DC chemotherapy (docetaxel,
60 mg/m2, day 1; and carboplatin, area under the curve,
6 mg·min−1·mL−1, day 1; both repeated every 21 days). The third
cycle was delayed because of her personal circumstances. A radiological
response was apparent after 2 cycles, but the disease was found to have
progressed after 4 cycles. The duration of the response was therefore
73 days, and progression free survival (PFS) after DC was 128 days
(Fig. 3). Over the course of the 4 treatment cycles, the patient suffered
grade 4 neutropenia, grade 2 anorexia, and fatigue, as deﬁned by the
Common Terminology Criteria for Adverse Events version 4.0. As a sec-
ond line therapy, she was administered irinotecan (60 mg/m2, days 1
and 8) and nedaplatin (a platinum analog, 80 mg/m2, day 1), repeated
every 21 days; however, the tumor progressed over the course of the
ﬁrst 2 cycles. Best supportive carewith a home palliative care physician
was offered, and she died 315 days after the ﬁrst administration of DC.Discussion
The standard chemotherapy formetastatic or recurrent cervical can-
cer is a combination of paclitaxel and cisplatin (TP). However, a recent
phase III trial for primarymetastatic or recurrent cervical cancer showed
that TC had similar efﬁcacywith less toxicity compared to TP (Kitagawa
Fig. 1. Histological diagnosis of glassy cell carcinoma (magniﬁcation: A, 40×; B, 400×).
20 Y. Ukita et al. / Gynecologic Oncology Reports 6 (2013) 19–21et al., 2012a). It should be noted though, that in the preceding phase II
trial for a similar population, the same authors found that the response
of adenocarcinoma/adenosquamous cell carcinoma to TC was lower
than that of squamous cell carcinoma (40% v.s. 66%) (Kitagawa et al.,
2012b). In another phase II trial for locally advanced or recurrent cervi-
cal cancer, Takekida et al. reported an overall response rate of 63.7%. In-
terestingly, in this study, the response rate was similar between non-
squamous and squamous cell carcinoma (68.9% v.s. 69.7%) amongC
BA
Fig. 2.A coronal 18F-ﬂuorodeoxyglucose (FDG)-positron emission tomography scan showi
(B) paraaortic lymph nodes, and (C) pelvic lymph node.chemo-naïve patients (Takekida et al., 2010). The reasons for the dis-
crepancy in the results obtained using TC and DC remain unclear. The
3-week schedule of paclitaxel administration might impact the re-
sponse of non-squamous cell cervical cancer, as demonstrated in a
phase IIII trial of paclitaxel used as an adjuvant therapy for breast cancer
(Sparano et al., 2008).
Based on these previous studies, we used DC to treat this patient.
Although this gave an initial response, its duration was only 73 days,ng signiﬁcant FDG uptake in the (A) retroperitoneal and supraclavicular lymph nodes,
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Fig. 3. Radiological and serological response during chemotherapy consisting of docetaxel and carboplatin (DC). The duration of the response and the progression free survival were
73 days and 128 days, respectively. The radiological response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The sum of the diameters
in the short axis of the left paraaortic and right external iliac lymph nodes is shown.
21Y. Ukita et al. / Gynecologic Oncology Reports 6 (2013) 19–21and the progression free survival was only 128 days. The subsequent
chemotherapy consisted of irinotecan and nedaplatin. Although this
has been reported to be effective for recurrent squamous cell carci-
noma of the cervix (Ohara et al., 2013), it was not effective in this
case. Nonetheless, this is the ﬁrst report of a response DC regimen
in a patient with GCC, and we suggest that its efﬁcacy should be fur-
ther investigated.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.References
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